tiprankstipranks
Trending News
More News >
Abbott Laboratories (ABT)
:ABT
US Market
Advertisement

Abbott Laboratories (ABT) Earnings Dates, Call Summary & Reports

Compare
8,628 Followers

Earnings Data

Report Date
Oct 15, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
1.3
Last Year’s EPS
1.21
Same Quarter Last Year
Based on 19 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Jul 17, 2025|
% Change Since: 4.85%|
Earnings Call Sentiment|Neutral
Abbott experienced strong growth in several segments, particularly in Medical Devices and EPD, and achieved significant EPS growth. However, challenges persist in the Diagnostics segment due to declining COVID testing sales and issues in the China market. The impact of tariffs also presents a headwind, but overall performance remains resilient.
Company Guidance -
Q3 2025
During the second quarter of 2025, Abbott demonstrated robust financial performance with high single-digit organic sales growth, excluding COVID testing sales, amounting to 7.5% for the quarter and 8% for the first half of the year. The company also achieved over 100 basis points of margin expansion in both gross and operating margins, alongside a 16% sequential growth in adjusted earnings per share, reaching $1.26, which exceeded consensus estimates. Despite a 1.5% decline in diagnostics sales due to reduced COVID testing and challenges in China, Abbott's core lab diagnostics grew by 8% outside China. Nutrition sales rose by 3.5% driven by a 6.5% increase in adult nutrition, while Medical Devices saw a 12% growth, propelled by double-digit growth in diabetes care, heart failure, and electrophysiology. The company's strategic initiatives, including biosimilar regulatory submissions in emerging markets and advancements in mitral valve replacement technologies, underscore its commitment to sustainable growth and innovation. Abbott forecasts continued high single-digit growth with expectations for favorable foreign exchange impacts and resilience against headwinds in diagnostics.
Strong Sales Growth
Abbott delivered high single-digit sales growth excluding COVID testing, with a 7.5% increase in the second quarter and an 8% increase in the first half of 2025.
Record Performance in EPD
Sales in EPD grew nearly 8% in the quarter, surpassing $1 billion in quarterly sales for the first time, driven by strong performance in key markets including India, China, and other regions.
Medical Devices Success
Medical Devices sales grew 12% driven by double-digit growth in diabetes care, heart failure, structural heart, electrophysiology, and cardiac rhythm management.
Diabetes Care Growth
Sales of continuous glucose monitors reached $1.9 billion in the quarter, growing 19.5%.
EPS Growth
Second quarter adjusted earnings per share were $1.26, reflecting 11% growth versus the prior year and 16% growth on a sequential basis.

Abbott Laboratories (ABT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ABT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 15, 2025
2025 (Q3)
1.30 / -
1.21
Jul 17, 2025
2025 (Q2)
1.26 / 1.26
1.1410.53% (+0.12)
Apr 16, 2025
2025 (Q1)
1.07 / 1.09
0.9811.22% (+0.11)
Jan 22, 2025
2024 (Q4)
1.34 / 1.34
1.1912.61% (+0.15)
Oct 16, 2024
2024 (Q3)
1.20 / 1.21
1.146.14% (+0.07)
Jul 18, 2024
2024 (Q2)
1.10 / 1.14
1.085.56% (+0.06)
Apr 17, 2024
2024 (Q1)
0.95 / 0.98
1.03-4.85% (-0.05)
Jan 24, 2024
2023 (Q4)
1.19 / 1.19
1.0315.53% (+0.16)
Oct 18, 2023
2023 (Q3)
1.10 / 1.14
1.15-0.87% (-0.01)
Jul 20, 2023
2023 (Q2)
1.05 / 1.08
1.43-24.48% (-0.35)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ABT Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 17, 2025
$131.74$120.51-8.52%
Apr 16, 2025
$125.66$129.12+2.75%
Jan 22, 2025
$115.73$116.71+0.85%
Oct 16, 2024
$114.40$116.14+1.52%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Abbott Laboratories (ABT) report earnings?
Abbott Laboratories (ABT) is schdueled to report earning on Oct 15, 2025, Before Open (Confirmed).
    What is Abbott Laboratories (ABT) earnings time?
    Abbott Laboratories (ABT) earnings time is at Oct 15, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ABT EPS forecast?
          ABT EPS forecast for the fiscal quarter 2025 (Q3) is 1.3.

            Abbott Laboratories (ABT) Earnings News

            ABT Earnings: Abbott Laboratories Stock Slips on Mixed Q1 Results
            Premium
            Market News
            ABT Earnings: Abbott Laboratories Stock Slips on Mixed Q1 Results
            3M ago
            ABT Earnings: Abbott Posts Mixed Q4 Results, Issues FY25 Growth Outlook
            Premium
            Market News
            ABT Earnings: Abbott Posts Mixed Q4 Results, Issues FY25 Growth Outlook
            6M ago
            ABT Earnings: Strong Medical Device Sales Help Abbott Beat Q3 Estimates
            Premium
            Market News
            ABT Earnings: Strong Medical Device Sales Help Abbott Beat Q3 Estimates
            10M ago
            ABT Earnings: Abbott’s Q3 Earnings Top Street Expectations
            Premium
            Market News
            ABT Earnings: Abbott’s Q3 Earnings Top Street Expectations
            1y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis